信号转导
癌症研究
表皮生长因子受体抑制剂
酪氨酸激酶
细胞信号
表皮生长因子受体
生物
ERBB3型
癌症
ErbB公司
癌细胞
受体酪氨酸激酶
细胞生物学
遗传学
作者
Saloni Ramani,Sayalee Samant,Sonal M Manohar
出处
期刊:Future Medicinal Chemistry
[Newlands Press Ltd]
日期:2022-09-01
卷期号:14 (17): 1267-1288
被引量:12
标识
DOI:10.4155/fmc-2021-0343
摘要
EGFR is a member of the ERBB family. It plays a significant role in cellular processes such as growth, survival and differentiation via the activation of various signaling pathways. EGFR deregulation is implicated in various human malignancies, and therefore EGFR has emerged as an attractive anticancer target. EGFR inhibition using strategies such as tyrosine kinase inhibitors and monoclonal antibodies hinders cellular proliferation and promotes apoptosis in cancer cells in vitro and in vivo. EGFR inhibition by tyrosine kinase inhibitors has been shown to be a better treatment option than chemotherapy for advanced-stage EGFR-driven non-small-cell lung cancer, yet de novo and acquired resistance limits the clinical benefit of these therapeutic molecules. This review discusses the cellular signaling pathways activated by EGFR. Further, current therapeutic strategies to target aberrant EGFR signaling in cancer and mechanisms of resistance to them are highlighted.
科研通智能强力驱动
Strongly Powered by AbleSci AI